Why Bicuspid Aortic Valve Disease Is an Aortic Problem, Not Just a Valve Problem
Most patients who learn they have a bicuspid aortic valve are told something along the lines of: "You have a two-leaflet valve instead of three. We'll keep an eye on it." That statement is accurate, but it is dangerously incomplete.
As a surgeon whose practice is focused on surgery of the aorta and great vessels, I see the downstream consequences of that incomplete framing every week. A patient arrives with a severely dilated ascending aorta — five, sometimes five and a half centimeters — and the referring team is still focused exclusively on the valve gradient. The aorta has been quietly enlarging for years, and nobody connected the dots.
Here is the reality: bicuspid aortic valve disease is a disorder of the entire proximal aorta. The same developmental abnormality that produces a two-leaflet valve also weakens the wall of the ascending aorta. According to the ACC/AHA guidelines, up to 40% of patients with BAV will develop clinically significant ascending aortic dilation at some point in their lives. Some of those patients will dissect. And aortic dissection, as I can tell you from operating on it at 2 a.m., is a catastrophe we should be working to prevent — not react to.
This article is written for patients and families who are trying to understand what a bicuspid aortic valve diagnosis means, what the BAV treatment options actually are, and how to think about bicuspid valve surgery timing before a complication narrows your choices.
Understanding BAV Treatment Options: Surveillance, Medical Therapy, and Surgery
Not every bicuspid aortic valve needs surgery. Some never will. But every bicuspid aortic valve needs a plan, and that plan should account for both the valve and the aorta. Here is the spectrum of management:
1. Active Surveillance
If your valve is functioning well — no significant stenosis (narrowing) or regurgitation (leaking) — and your ascending aorta measures under 4.0 cm, you likely need monitoring rather than intervention. That monitoring should include:
- An echocardiogram at least every one to two years, sometimes annually depending on your baseline measurements and rate of change
- Periodic CT angiography or MRI of the chest to accurately measure the ascending aorta (echocardiography alone can underestimate aortic dimensions)
- Blood pressure control, ideally targeting less than 130/80 mmHg
The key word here is active. Surveillance does not mean doing nothing. It means measuring precisely, trending over time, and having predefined thresholds that trigger a change in plan.
2. Medical Therapy
There is no medication that reverses bicuspid aortic valve disease. However, aggressive blood pressure management with beta-blockers or ARBs can reduce the rate of aortic dilation. Studies in patients with Marfan syndrome and related aortopathies suggest that losartan may slow aortic root growth, and many of us extrapolate cautiously to BAV patients with progressive dilation. Statins may be considered if there is coexisting hyperlipidemia, but they do not slow valvular calcification in a clinically meaningful way based on current evidence.
3. Surgical Intervention
Surgery remains the definitive treatment for bicuspid aortic valve disease that has progressed to severe valve dysfunction, significant aortic dilation, or both. The specific operation depends on what needs to be fixed, and this is where having a surgeon who understands the full disease matters enormously.
The surgical options include:
- Aortic valve replacement — mechanical or bioprosthetic — for severe aortic stenosis or regurgitation
- Aortic valve repair — in selected patients with regurgitation and favorable valve anatomy, repair can preserve the native valve and avoid lifelong anticoagulation
- Ascending aorta replacement — a Dacron graft to replace the dilated segment, often performed as a combined procedure with valve surgery
- Aortic root replacement (Bentall procedure or valve-sparing root replacement) — when the sinuses of Valsalva are dilated along with the ascending aorta
- Combined valve and ascending aorta replacement — which in my practice is the most common scenario, because by the time surgery is indicated, both structures are affected
If you have been told you need surgery and are trying to understand your specific options, using a tool like our free cardiac surgery risk calculator can help you begin to frame the conversation with your surgical team.
Bicuspid Valve Surgery Timing: When Watchful Waiting Becomes Harmful Delay
This is the question I spend the most time discussing with patients, and it is the question most likely to benefit from a second set of expert eyes.
Bicuspid valve surgery timing is not a single decision point. It is a moving target that depends on multiple variables measured over time. The current ACC/AHA guidelines provide the following thresholds, which I use as a framework — not a rigid checklist:
Indications Related to the Valve
- Severe aortic stenosis with symptoms (chest pain, shortness of breath, syncope) — surgery is indicated and should not be delayed
- Severe aortic stenosis without symptoms — surgery should be strongly considered if the left ventricle is beginning to show strain (ejection fraction dropping below 55%, abnormal exercise response, or very severe stenosis with a peak velocity above 5 m/s)
- Severe aortic regurgitation with symptoms — surgery is indicated
- Severe aortic regurgitation without symptoms — surgery is recommended when the left ventricle begins to dilate (end-systolic dimension above 50 mm or ejection fraction below 55%)
Indications Related to the Aorta
- Ascending aorta diameter of 5.5 cm or greater — surgery is recommended in most patients
- Ascending aorta diameter of 5.0 cm or greater — surgery should be considered if there are additional risk factors: rapid growth (more than 0.5 cm per year), family history of aortic dissection, or planned aortic valve surgery anyway
- Ascending aorta diameter of 4.5 cm or greater at the time of valve surgery — most experienced aortic surgeons, including myself, will replace the ascending aorta concomitantly, because the incremental risk of adding the aortic graft is small and the long-term benefit of preventing future dissection or reoperation is substantial
I want to be direct about something. The difference between operating at 4.5 cm during planned valve surgery and waiting until the aorta reaches 5.5 cm on its own is not academic. It is the difference between a planned, controlled, combined operation and a potential emergency. In my experience operating on acute aortic dissections, approximately 20-25% of the patients I see in that emergency setting have a bicuspid aortic valve that was being "watched."
If you are uncertain whether your measurements warrant intervention, or if you have been told to wait and something feels off about that advice, getting a second opinion from a specialist is a reasonable and important step.
What BAV Patients Should Ask Their Surgical Team
Not all cardiac surgeons operate on the aorta with the same frequency or expertise. BAV disease that involves both the valve and the ascending aorta is best managed by a team experienced in combined procedures. Here are questions I encourage every patient to ask:
- How many combined valve-and-aorta operations do you perform per year? Volume matters. Studies consistently show that surgical outcomes for aortic procedures improve at centers performing higher volumes.
- Will you replace my ascending aorta if it measures between 4.0 and 4.5 cm at the time of valve surgery? The answer to this question reveals a surgeon's philosophy about prophylactic aortic management and their comfort with the added technical complexity.
- Am I a candidate for valve repair rather than replacement? Not everyone is, but if your anatomy is favorable and the surgeon has expertise in BAV repair techniques, preserving your native valve has real advantages — particularly for younger patients.
- What imaging have you reviewed, and do you want additional imaging before making a surgical plan? A CT angiogram or cardiac MRI is essential for operative planning. If your surgeon is basing the plan solely on echocardiography, ask why.
- What is my estimated surgical risk? This should be a specific number based on validated scoring systems (STS risk score), not a vague reassurance.
The Role of TAVR in Bicuspid Aortic Valve Disease
Patients often ask me about transcatheter aortic valve replacement (TAVR) as an alternative to open surgery for BAV. This is an important topic that deserves a clear answer.
TAVR has transformed the treatment of aortic stenosis in elderly and high-risk patients with trileaflet (three-leaflet) aortic valves. However, its role in bicuspid aortic valve disease is limited and evolving. The irregular, asymmetric anatomy of a bicuspid valve creates challenges for transcatheter deployment — including higher rates of paravalvular leak and asymmetric expansion. More importantly, TAVR does nothing to address the ascending aorta, which is the part of the disease that can kill you suddenly.
For younger and intermediate-risk BAV patients — which describes the majority of the BAV population — open surgery remains the standard of care. This is not an ideological position. It is a reflection of the data and the disease biology. When you have a condition that affects both the valve and the vessel wall, you need an operation that can address both.
Why a Second Opinion Matters in Bicuspid Aortic Valve Management
BAV is one of the conditions where I most frequently see management plans that are either too conservative or too narrowly focused. The patient with a 4.8 cm ascending aorta who has been told to "come back in a year." The patient who is offered isolated valve replacement without any discussion of the aorta. The patient who is told TAVR is an option when their anatomy clearly favors open surgery.
These are not bad-faith recommendations. They reflect the reality that BAV sits at the intersection of valvular heart disease and aortic disease, and not every cardiologist or surgeon has deep experience in both domains. A specialist second opinion can clarify whether your current plan is appropriately comprehensive.
At WhiteGloveMD, our review process is designed to give you access to fellowship-trained cardiac surgical specialists who will evaluate your imaging, your hemodynamic data, and your clinical trajectory — and provide a clear, written opinion on whether the proposed plan is sound or whether a different approach should be considered. You can see exactly how our process works here.
If you are living with a bicuspid aortic valve and have been told you need surgery — or told you do not need surgery yet and want to be sure that is the right call — a WhiteGloveMD second opinion can help you make this decision with confidence. Your valve and your aorta deserve a plan that accounts for both.